Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer |
| |
Authors: | Leonard Gregory D Dahut William L Gulley James L Arlen Philip M Figg William D |
| |
Abstract: | Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|